About HIGHTIDE-B Company

HighTide Therapeutics, Inc. (HighTide Therapeutics, Inc.) is a globally integrated new biotechnology company focusing on major unmet clinical needs in the fields of metabolic diseases and digestive diseases. Under the leadership of an experienced international executive team and a world-class scientific advisory board, the company develops first-in-class, multi-functional, and multi-indication original and innovative drugs based on innovation at the source, with the goal of comprehensive clinical benefit and overall health improvement for patients. Based on independent intellectual property rights, the company has built a rich product pipeline, promoted multiple middle- and late-stage clinical trials around the world, and developed indications such as non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC). As the first multi-target novel molecular entity of its kind, HTD1801 was granted 2 “Fast Track Qualifications” and 1 “Orphan Drug Qualification” by the US FDA, and received major special scientific and technological support from the “13th Five-Year Plan” “Major New Drug Creation”.